プラズマ細胞白血病：ゲノムの特徴とその臨床的実行可能性を探る上での潜在的な関連性
Meera Mohan1, Natalie Danziger2, Othman Salim Akhtar1
1Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
Blood advances
|February 24, 2026
まとめ
形質細胞白血病（PCL）は多発性骨髄腫（MM）と比較して異なる遺伝的変化を示す。次世代シーケンシングにより、PCLにおける特定の変異と転座が特定され、治療標的となる可能性がある。
さらに関連する動画
関連する概念動画
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
01:29Pharmacogenomics: Identification of New Drug Targets
49
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
49
01:21Lineage Commitment
4.5K
Commitment is the process whereby stem cells:
4.5K